<DOC>
	<DOCNO>NCT00227591</DOCNO>
	<brief_summary>This phase II trial study well give lenalidomide together prednisone work treat patient myelofibrosis . Lenalidomide may stop growth myelofibrosis block blood flow cancer . It may also stimulate immune system different way stop cancer cell grow . Drugs use chemotherapy , prednisone , work different way stop growth cancer cell , either kill cell stop divide . Giving lenalidomide together prednisone may kill cancer cell .</brief_summary>
	<brief_title>Lenalidomide Prednisone Treating Patients With Myelofibrosis</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To evaluate rate complete partial remission treatment combination lenalidomide prednisone patient myelofibrosis myeloid metaplasia . SECONDARY OBJECTIVES : I . To examine drug toxicity . II . To examine duration response . III . To examine effect treatment bone marrow fibrosis , angiogenesis , cytogenetics . OUTLINE : For course 1 2 , patient receive oral lenalidomide daily oral prednisone daily day 1-28 . For course 3 , patient receive oral lenalidomide daily day 1-28 oral prednisone day 1 , 3 , 5 , 7 , 9 , 11 , 13 , 15 , 17 , 19 , 21 , 23 , 25 , 27 . Patients stable respond disease course 3 receive oral lenalidomide alone daily day 1-28 course 4-6 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 1 year every 6 month 5 year study entry .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patient must diagnose myelofibrosis myeloid metaplasia ( MMM ) ; agnogenic myeloid metaplasia , postpolycythemic myeloid metaplasia , postthrombocythemic myeloid metaplasia include NOTE : Diagnosis must confirm central pathology review ; diagnostic sample must submit ; patient may register begin treatment base local pathology review . If central review confirm patient 's eligibility participate trial , protocol treatment must discontinue Patient must discontinue chemotherapy ( hydroxyurea , alpha interferon , anagrelide , myelosuppressive agent , thalidomide , experimental therapy ) well growth factor systemic use corticosteroid &gt; = 28 day prior start study drug All nonhematologic toxicity must resolve = &lt; grade 1 Patient must lenalidomidena√Øve ( never treat lenalidomide ) ECOG performance status ( PS ) 0 , 1 , 2 study entry Hemoglobin level = &lt; 10 g/dL transfusiondependent Absolute neutrophil count &gt; = 1,000 uL Platelet count &gt; = 100,000 uL Serum creatinine = &lt; 2.0 mg/dL Total bilirubin = &lt; 2.0 mg/dL ( elevate ; direct bilirubin = &lt; 2.0 mg/dL ) AST ( SGOT ) = &lt; 3 x ULN unless attribute hepatic extramedullary hematopoiesis Women must pregnant breastfeed study involve investigational agent whose genotoxic , mutagenic , teratogenetic effect develop fetus newborn unknown ; woman childbearing potential sexually active , must use 2 accepted method birth control time 4 week prior lenalidomide treatment , lenalidomide treatment , 4 week lenalidomide treatment finish ; sexually active male must use latex condom contraception study 4 week treatment lenalidomide end All female childbearing potential must blood test 1014 day prior start lenalidomide treatment rule pregnancy ; another blood test rule pregnancy must do 24 hour prior start treatment lenalidomide Patient must condition , include presence laboratory abnormality , , base physician 's opinion , place patient unacceptable risk he/she participate study confounds ability interpret data study Patient must know hypersensitivity thalidomide lenalidomide Patient must know positive status HIV infectious hepatitis type A , B C Patient must active malignancy NOTE : SWOG patient strongly encourage register SWOG9007 ( `` Cytogenetic Studies Leukemia Patients '' ) ; SWOG institution register patient SWOG9007 follow instruction specimen submission</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>